8014 Background: MET and VEGF are important in mediating NSCLC tumorigenesis and
EGFR TKI resistance. We hypothesized that treatment with the dual MET-VEGF inhibitor …

Objectives Clinical trials with first-and second-generation epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) reported severe adverse events (SAEs) in 6%–49 …

Background ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI)
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …

Introduction Osimertinib is a standard first-line treatment for non–small cell lung cancer
(NSCLC) harboring mutations of the epidermal growth factor receptor gene (EGFR) …

Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR TKIs) are
established first-line treatments among patients with metastatic non-small cell lung cancer …

7011 Background: Tarceva™(erlotinib) is a potent reversible HER1/EGFR tyrosine kinase
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …

2516 Background: REGN1400 (R) is a fully human mAb targeting ErbB3. Preclinically, dual
inhibition of ErbB3 and EGFR confers augmented antitumor potency. This first-in-human …

Abstract Introduction The phase II JO25567 study compared the efficacy and safety of
erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal …

BACKGROUND This study compared the efficacy and safety of treatment with erlotinib plus
pazopanib versus erlotinib plus placebo in patients with previously treated advanced non …

7520 Background: OPTIMAL demonstrated the superiority of erlotinib (E) vs gemcitabine/
carboplatin (G/C) in terms of progression-free survival (PFS), objective response rate (ORR) …